Jasper Therapeutics (NASDAQ:JSPR) Posts Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Jasper Therapeutics (NASDAQ:JSPR) posted its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17, FiscalAI reports.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock traded down $0.07 on Friday, reaching $0.79. 567,510 shares of the company were exchanged, compared to its average volume of 2,265,872. The stock’s 50 day moving average price is $0.59 and its 200-day moving average price is $0.91. Jasper Therapeutics has a 1-year low of $0.32 and a 1-year high of $3.14. The company has a market cap of $22.12 million, a P/E ratio of -0.24 and a beta of 3.02.

Analyst Upgrades and Downgrades

A number of research firms have commented on JSPR. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Piper Sandler started coverage on Jasper Therapeutics in a research note on Wednesday. They set an “overweight” rating and a $2.00 target price on the stock. Royal Bank Of Canada set a $3.00 target price on Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th. Wall Street Zen downgraded Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Knott David M Jr raised its position in shares of Jasper Therapeutics by 5.8% during the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock worth $332,000 after acquiring an additional 10,000 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Jasper Therapeutics during the 1st quarter worth approximately $46,000. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics during the second quarter worth approximately $78,000. Renaissance Technologies LLC lifted its stake in Jasper Therapeutics by 9.0% in the fourth quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after buying an additional 18,683 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new stake in shares of Jasper Therapeutics in the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.